New Drug Prescription Cost Rule Allows Negotiation Patient Outcomes MIPS Reporting
How the New Drug Prescription Rule Facilitates Physicians? As the new proposed rules will come into action, drug manufacturers will have more say in the payment arrangements. In addition, the patients' outcomes will make clinicians accountable for their services, and they can invest in opportunities to earn more revenue, particularly via MIPs Reporting . Right now, the payment arrangements are made on the quantity of the product rather than the quality of the product. In such circumstances, it is impossible to move towards innovation; consequently, medical billing companies can't drive value to the claims nor can payers promote access to innovative therapies or drugs due to cost prohibitions. CMS promised to address rising healthcare expenses, administrative burden, and the lack of quality systems, and they are gradually settling every concern that is restricting progression. In the same context, recently, we heard the great news, especially for medical billing and QPP MIPS ...